Home > Boards > US Listed > Biotechs > ImmunoGen, Inc. (IMGN)

The Piper Jaffray presentation may have had an

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
skitahoe Member Profile
 
Followed By 76
Posts 3,892
Boards Moderated 0
Alias Born 08/14/03
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 2/14/2020 5:20:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:54:02 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 12:40:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/14/2020 6:38:07 AM
ImmunoGen Reports Recent Progress and 2019 Financial Results Business Wire - 2/14/2020 6:30:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2020 2:59:40 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/12/2020 3:04:36 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 7:53:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:28:30 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:28:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:27:09 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:26:34 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:25:29 AM
Schedule 13g Edgar (US Regulatory) - 2/10/2020 9:11:28 AM
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Business Wire - 2/6/2020 4:30:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/5/2020 11:50:20 AM
ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 2/3/2020 4:30:00 PM
ImmunoGen Announces Conference Call to Discuss Its 2019 Operating Results Business Wire - 1/30/2020 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/27/2020 4:13:56 PM
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Business Wire - 1/27/2020 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/23/2020 4:07:59 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/23/2020 4:06:26 PM
ImmunoGen Announces Pricing of Public Offering of Common Stock Business Wire - 1/22/2020 8:44:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/22/2020 4:10:55 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/22/2020 4:08:19 PM
skitahoe   Wednesday, 12/04/19 09:57:48 PM
Re: whytestocks post# 643
Post # of 665 
The Piper Jaffray presentation may have had an influence as well, I'm listening to it as I type, but saw where others were impressed with it.

I believe the bigger news will come out of ASH where hopefully the entire presentation will become available. Among other things I understand that a fast path to approval may be available for IMGN632 in one of the indications being treated. This could have the potential of an approval prior to the conclusion of the Phase 3 for IMGN853, but it's also indicated that a partnership there is certainly in discussion.

Gary




Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist